Literature DB >> 8690340

Insurance coverage for experimental technologies.

E P Steinberg1, S Tunis, D Shapiro.   

Abstract

As the number and cost of new technologies grow, it is increasingly important that we develop sound policies for payment for those technologies while their clinical impacts are being defined. Such policies need to balance social interests in promotion of innovation, early access to promising technology, patient safety, control of health care costs, and return on investment. We present a rationale, policy options, and a proposal for insurance coverage of experimental technology.

Entities:  

Keywords:  Biomedical and Behavioral Research; Health Care and Public Health

Mesh:

Year:  1995        PMID: 8690340     DOI: 10.1377/hlthaff.14.4.143

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  4 in total

1.  Randomized Trials of Proton Therapy: Why They Are at Risk, Proposed Solutions, and Implications for Evaluating Advanced Technologies to Diagnose and Treat Cancer.

Authors:  Justin E Bekelman; Andrea Denicoff; Jeffrey Buchsbaum
Journal:  J Clin Oncol       Date:  2018-07-09       Impact factor: 44.544

2.  Reference pricing with evidence development: a way forward for proton therapy.

Authors:  Justin E Bekelman; Stephen M Hahn
Journal:  J Clin Oncol       Date:  2014-04-21       Impact factor: 44.544

3.  Paying for prevention: challenges to health insurance coverage for biomedical HIV prevention in the United States.

Authors:  Kristen Underhill
Journal:  Am J Law Med       Date:  2012

4.  Assessing personalized medicines in Australia: a national framework for reviewing codependent technologies.

Authors:  Tracy Merlin; Claude Farah; Camille Schubert; Andrew Mitchell; Janet E Hiller; Philip Ryan
Journal:  Med Decis Making       Date:  2012-08-15       Impact factor: 2.583

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.